<DOC>
	<DOCNO>NCT00485875</DOCNO>
	<brief_summary>The purpose study ass change ADHD symptom tolerability medication child adolescent switch stimulant atomoxetine .</brief_summary>
	<brief_title>Safety Efficacy Switching From Stimulant Medication Atomoxetine Children Adolescents With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<criteria>Patients must least 6 year age yet 18 year age completion visit 6 Patients must meet DSMIV diagnostic criterion ADHD ( subtype ) Patients must laboratory result show significant abnormality ( significant would include laboratory deviation require acute medical intervention medical evaluation ) Patients must normal intelligence assess investigator ( , without general impairment intelligence likely , investigator 's judgment , achieve score great equal 70 IQ test ) Patients must able swallow capsule Patients weigh less 22 kg 70 kg study entry Patients history Bipolar I Bipolar II Disorder , psychosis , pervasive developmental disorder Patients history seizure disorder ( febrile seizure ) prior EEG abnormality relate epilepsy , patient take ( currently take ) anticonvulsant seizure control Patients history severe allergies one class medication , multiple adverse drug reaction Patients glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>